Ultraviolet Radiation Mutagenesis of Hedgehog Pathway Genes in Basal Cell Carcinomas  by Aszterbaum, Michelle et al.
Ultraviolet Radiation Mutagenesis of Hedgehog Pathway Genes
in Basal Cell Carcinomas
Michelle Aszterbaum, Jenna Beech, and Ervin H. Epstein Jr
Department of Dermatology, University of California San Francisco, San Francisco, California, U.S.A.
The identification of mutations in Hedgehog (HH) path-
way genes in some basal cell carcinomas (BCC) and the
detection of HH pathway dysregulation in almost all
BCC confirms the importance of this developmental
regulatory pathway in human BCC tumorigenesis. More-
over, the occurrence of UVB signature mutations in key
HH pathway genes in BCC provides the first genetic
evidence that UV radiation (UVR) may be the principal
mutagen involved in BCC tumorigenesis. We review
herein current advances in the understanding of the role
Although ultraviolet radiation (UVR) is considered theprimary mutagen involved in basal cell carcinoma (BCC)tumorigenesis, there is a paucity of experimental data toconfirm this association. Until recently, research on thepathogenesis of BCC has been hampered by the lack of
animal models and by a limited understanding of the genetic basis of
the cancer. The identification of mutations in Hedgehog (HH) pathway
genes including PATCHED (PTC), SONIC HEDGEHOG (SHH),
and SMOOTHENED (SMO) has expanded our understanding of the
genetic basis of BCC and facilitated the development of in vitro and
in vivo models of BCC. In light of these recent advances, we will
review epidemiologic and genetic evidence linking UVR to BCC
tumorigenesis and PTC mutagenesis and the potentially collaborative
role of mutations in other oncogenes and tumor suppressor genes in
BCC tumorigenesis.
EPIDEMIOLOGIC EVIDENCE
Basal cell carcinoma is the most common human cancer, affecting an
estimated 750 000 Americans per year (Miller and Weinstock, 1994).
BCC incidence is rising – 3% annually in two sampled US geographic
regions between 1971 and 1978 (Fears and Scotto, 1982), and doubling
in a 10-y period in Stockholm, Sweden (Wallberg and Skog, 1991).
This increasing incidence is commonly attributed to lifestyle changes
favoring sun exposure in spite of efforts to educate the public on the
dangers of UV exposure. It is estimated that 28% of Caucasians
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of the HH pathway in BCC tumorigenesis including
transgenic and knock-out animal models of HH pathway
dysregulation. Furthermore, we summarize abnormalit-
ies in other tumor suppressors and oncogenes including
ras and p53 and evidence for interactions between these
regulatory genes and the HH pathway. Key words: basal cell
carcinoma/Hedgehog pathway/PATCHED/p53 and ultraviolet
radiation. Journal of Investigative Dermatology Symposium
Proceedings 4:41–45, 1999
born after 1994 will develop a BCC in their lifetime (Miller and
Weinstock, 1994).
A wealth of epidemiologic data establishes the importance of UV
radiation exposure to BCC tumorigenesis. For example, these tumors
occur on sites commonly exposed to sunlight – primarily the head and
neck (approximately 66%) (Giles et al, 1988) – they occur with greater
frequency in those with fair skin, an inability to tan, and a tendency
to freckle or sunburn (Kricker et al, 1991), and they occur rarely in
African-Americans (Scott et al, 1983). There is also a direct correlation
between increasing BCC incidence and increasing equatorial proximity
(Kricker et al, 1991) and thus higher solar irradiance. This correlation
is further confirmed by studies finding a lower incidence of BCC in
migrants from high latitude countries (low levels of childhood UV
exposure) to Australia (low latitude) than in native-born Australians
(Giles et al, 1988).
MOLECULAR PATHOGENESIS
In 1996, two groups simultaneously reported the identification of
mutations in the PTC gene in sporadic BCC and in patients with basal
cell nevus syndrome (BCNS) (Hahn et al, 1996b; Johnson et al,
1996). BCNS is an autosomal dominant disorder characterized by the
development of multiple BCC, central nervous system (CNS) tumors
(medulloblastomas and meningiomas), jaw keratocysts, and skeletal
abnormalities (Gorlin, 1987). BCNS-associated BCC and jaw cysts
retain the mutant germ-line PTC allele but lose the wild-type (WT)
allele by loss of large chromosomal fragments at 9q (Bonifas et al, 1994;
Levant et al, 1996). PTC gene mutations and loss of the remaining
WT allele have also been identified in sporadic medulloblastomas and
meningiomas (11%), suggesting a common genetic basis for the sporadic
and syndrome-associated cancers (Raffel et al, 1997; Vorechovsky et al,
1997; Wolter et al, 1997; Xie et al, 1997). In accordance with Knudson’s
two hit hypothesis, BCNS patients – born with only one functional
PTC allele – are susceptible to developing these rare CNS tumors and
to developing BCC in greater numbers (tens to hundreds), and at a
younger average age than most sporadic cases.
The most common gross genetic alteration found in sporadic BCC
(68%) is loss of heterozygosity (LOH) at the region of the PTC locus
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(9q22) (Gailani et al, 1996a). LOH at 9q22 can be detected in
small BCC (,1 cm diameter) and tumors of varying histology and
invasiveness, but does not correlate with tumor aggressiveness (Gailani
et al, 1996a). These findings suggest that LOH at the region of the
PTC locus may be an early event in BCC tumorigenesis. Interestingly,
although UV exposure is an obvious risk factor for sporadic BCC
tumorigenesis, investigators have found a poor correlation between
LOH at 9q and the predicted level of solar irradiance at the tumor site
(Gailani et al, 1996a). In one study, BCC located on sites of high solar
irradiance (the nose) had a lower incidence (56%) of 9q LOH than
body sites with lower or no UV exposure (76%). Moreover, there was
no statistically significant correlation between the presence of p53
UVB signature mutations (the selected surrogate marker of high solar
irradiance) and LOH at 9q. As the authors stated, however, UVB
radiation most commonly results in point mutations rather than gross
chromosomal rearrangements or deletions, and therefore 9q LOH (as
detected by loss of microsatellite markers in this study) is an insensitive
measure of UVB-induced mutagenesis. Since the publication of this
study, the identification of the PTC gene coding sequence has enabled
the detection of these UV-induced point mutations.
PTC gene mutations have been identified in less than one third of
screened BCC (37 of 137, 27%). Of those mutations that were
identified in sporadic BCC, approximately 40% are the C→T or
CC→TT transitions at dipyrimidine sites typical of UVB-induced
DNA damage, implicating UVB in PTC mutagenesis (Hahn et al,
1996b; Johnson et al, 1996; Gailani et al, 1996b; Unden et al, 1996;
Wolter et al, 1997; Aszterbaum et al, 1998; Reifenberger et al, 1998).
The incidence of these UV signature mutations in PTC in human
BCC appears to be within the wide range observed in other mammalian
genes in UV-irradiated cultured cells. For example, in vitro UV
irradiation of cultured repair-proficient human fibroblasts resulted in
hypoxanthine phosphoribosyltransferase (HPRT) gene mutations, of
which 37% were the C→T (or alternatively represented by G·C→A·T)
or CC→TT UV signature type (McGregor et al, 1991), and irradiation
studies of Chinese hamster ovary cells resulted in a 62% incidence of
G·C→A·T transitions in the adenine phosphoribosyltransferase gene
(APRT) (Drobetsky et al, 1987). The incidence of UVB signature
mutations in p53 in BCC and SCC occurring in Caucasians is 65%
and 67%, respectively (Brash et al, 1991; Pierceall et al, 1991b; Rady
et al, 1992; Campbell et al, 1993; Moles et al, 1993; Ziegler et al, 1993;
Kubo et al, 1994; van der Riet et al, 1994; Gailani et al, 1996b). Thus,
the greater UVB signature mutation rate in p53 compared with PTC
in nonmelanoma skin cancers implies that UVB plays a greater role in
p53 inactivation than in Ptc inactivation. Nevertheless, both are within
the wide range of signature mutation incidence in in vitro model
systems. The large variability in incidence of C→T and CC→TT
substitutions in in vitro UV mutagenesis studies fails to provide an
expected, baseline incidence rate of UV signature mutations in mamma-
lian cells, thus making it difficult to conclude with statistical certainty
that PTC gene mutagenesis is purely UV mediated.
The hh and ptc genes were first identified as important regulators of
Drosophila larval segment polarity (anterior-posterior axis) and imaginal
disc pattern development. In the developing fly and developing mouse,
ptc is expressed in target tissues of hedgehog (Hh), a diffusable protein.
The ptc protein is an integral membrane protein predicted to have 12
transmembrane domains. This model posits that Ptc protein inhibits
HH target gene expression through its interaction with the Smoothened
(Smo) protein, predicted to be a seven transmembrane protein
resembling a G protein-coupled receptor. According to this model,
Ptc inhibition of Smo is relieved upon binding of Sonic Hedgehog
(Shh) to Ptc (Chen and Struhl, 1996; Marigo et al, 1996) or following
mutational inactivation of Ptc. Smo signaling may activate transcription
of HH targets including PTC through activation of the putative
transcription factor, Gli (Fig 1). Therefore, mutational inactivation of
PTC and consequent loss of Ptc protein function results in increased
Ptc expression and the accumulation of high levels of PTC transcript –
high levels of PTC mRNA correspond with low levels of Ptc
protein function.
Whereas only 37% of BCC have identifiable PTC gene mutations,
in situ hybridization studies detect high levels of PTC message in
Figure 1. Hedgehog signaling pathway proteins are involved in BCC
tumorigenesis. Hh is a soluble protein, which binds and suppresses Ptc, a 12
transmembrane domain protein with two large extracellular loops. If not bound
to Hh, Ptc acts as a repressor of another transmembrane protein, Smoothened
(Smo). If Ptc is mutationally inactivated or Smo is mutationally activated,
Smo acts constituitively to activate downstream pathway targets including
transcription factor Gli. Gli acts intranuclearly to activate transcription
of PTC.
essentially all BCC, in contrast to the absence of message in normal
epidermal keratinocytes (Unden et al, 1997). In one recent report, 24
of 25 BCC studied demonstrated a significant increase in PTC
expression relative to normal skin (Reifenberger et al, 1998), and all
BCC having PTC upregulation also had upregulation of other HH
pathway components including SMO and Gli (Dahmane et al, 1997;
Wolter et al, 1997; Green et al, 1998; Xie et al, 1998). Of the putative
transcription factor Gli family genes (Gli1, Gli2, and Gli3), Gli1 is the
most highly expressed in human BCC. Gli1 RNA levels were reported
to be increased in 46 of 47 BCC examined, with the highest levels
being found in tumor nodules invading the dermis (Dahmane et al,
1997). Of note, Gli1 is not expressed in interfollicular human basal cells
but is expressed during the growing phase of follicular development.
Mutations in other HH pathway genes have been identified in
sporadic BCC, implying that the principal trigger for tumorigenesis is
not simply mutation of the PTC gene, but is more likely HH pathway
dysregulation. Xie et al (1998) described mutations in SMO in 6%
(three of 47) of human BCC at codons 535 or 562, and Reifenberger
et al (1998) reported SMO mutations in 13% of BCC (four of 31) at
codons 535 or 199. The codon 535 mutation results in an amino acid
substitution in a highly conserved region in the seventh transmembrane
domain. SMO mutations were identified only in one SMO allele in
each tumor, with retention of the WT allele, pointing to the oncogenic
potential of Smo. Co-precipitation studies indicated that the codon
535 and 562 mutations described by Xie et al (1998) did not affect
binding of Smo to pTC, although the fidelity of this attachment has
not yet been elucidated. Half of those BCC with SMO mutations
(two of four) also had mutations in PTC (Reifenberger et al, 1998).
BCC with SMO mutations all had upregulated expression of PTC
mRNA and Gli1 mRNA. Of note, one of the four SMO mutations
Reifenberger described in BCC from UV-exposed areas was a C→T
substitution; however, these limited data are insufficient to confirm
that UVR is a significant SMO mutagen.
The oncogenic potential of mutant SMO was further confirmed by
Xie et al by in vitro assays using rat embryonic fibroblasts (REF52).
Transfection of REF52 cells with adenovirus E1A and mutant (but
not WT) SMO converted the REF52 cells to a malignant phenotype,
i.e., foci formation over a confluent monolayer (Xie et al, 1998).
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Table I. Current in vivo models of basal cell carcinoma tumorigenesis
Species Genetic alteration Tumor type Capable of reproduction Reference
mouse Shh transgenic BCC No Oro et al, 1997
mouse Smomut transgenic BCC No Xie et al, 1998
frog Gli 1 transfection BCC No Dahmane et al, 1997
mouse ptc KO (1/2) BCC and trichoblastoma Yes Aszterbaum et al, manuscript in preparation
Moreover, in contrast to normal REF52 cells, cells from these foci
were able to grow in soft agar. From these in vitro studies it appears
that simple overexpression of SMO in mammalian cells is insufficient
for malignant transformation and that mutant expression is required.
Mutations in SHH have also been identified in sporadic BCC. Oro
et al (1997) reported the identification of identical SHH mutations at
codon 133 (His to Tyr) in a sporadic BCC (one of 43) and a
medulloblastoma (one of 14). The predicted activating-type mutation
is a C→T transition at the 39 cytosine of a dipyrimidine site and
therefore possibly represents a UVB signature mutation; however,
this limited data and the occurrence of the same mutation in a
medulloblastoma, clearly not a UV-related cancer, warrants a cautious
interpretation of these findings.
ANIMAL MODELS
Although in humans UV appears to be a causative factor in BCC
tumorigenesis, it has proved difficult to induce BCC in experimental
mice. Experimental mice commonly develop SCC in response to UV
irradiation, but only rarely develop BCC. The most successful studies
of BCC induction in mice have been by application of polyoxyethylene
sorbitan monostearate and DMBA (Merenemies, 1959; Della Porta
et al, 1960). In contrast, rats are susceptible to BCC tumorigenesis by
exposure to X-ray (Zackheim et al, 1964) and topical carcinogens
(Zackheim et al, 1959). Surprisingly, these rat BCC models have not
been widely used. Study of BCC tumorigenesis has also been hindered
by the inability to achieve sustained tumor growth of human BCC
transplanted onto SCID mice (n 5 10; Aszterbaum, unpublished data),
and by the difficulty of establishing BCC cell lines. Our increased
understanding of the role of HH pathway dysregulation in BCC
tumorigenesis, however, has enabled the development of animal models
that facilitate study of BCC pathogenesis.
Oro et al (1997) described a keratin 14 (K-14) promotor driven
SHH transgenic mouse that expressed high levels not only of SHH
RNA but also of PTC RNA in the epidermis, suggestive of target
gene activation. K-14 SHH transgenic mice displayed several pheno-
typic findings similar to BCNS patients, including polydactyly, spina
bifida, and multiple BCC-like epidermal proliferations throughout
their skin surface early in skin development. Because K-14 SHH mice
are not viable beyond the perinatal period, tumor progression was
examined by transplantation of embryonic skin onto SCID mice;
however, the BCC-like growths failed to enlarge further and displayed
partial mature hair follicle differentiation. A second mouse model of
BCC tumorigenesis was described by Xie et al (1998) in which a
keratin 5 (K-5) promoter drove expression of mutant (codon 535)
SMO (SMOmut) in the epidermis. These mice express high levels of
mutant SMO in the basal layer of the epidermis and develop BCC-like
cutaneous growths, establishing the role of SMO in BCC tumorigenesis.
These mice, however, fail to produce viable offspring and are therefore
impractical models for further study (Table I).
An amphibian model also links BCC tumorigenesis to HH pathway
dysregulation. Dahmane et al (1997) reported the overexpression of
Gli1 in frog embryo epidermis by injection of ectodermal cells with a
Gli1 construct. Transfected frog embryos demonstrated ectopic expres-
sion of Gli1 and, importantly, activation of HH target genes. Moreover,
frog embryos developed abnormal BCC-like tumors, suggesting that
Gli1 overexpression may be sufficient to result in BCC tumorigenesis.
This amphibian model and the mouse models herein described provide
powerful evidence that BCC pathogenesis can result from disruption
of at least three important regulatory points in the HH pathway.
The PTC knockout (KO) mouse model, first described by Goodrich
et al (1997), confirms the importance of PTC in mammalian develop-
ment and BCC tumorigenesis. These ptc KO mice have a deletion of
exons 1 and 2 and insertion of lacZ reporter gene at the deleted site.
Although homozygous KO (ptc–/–) mice die at embryonic day 8.5,
the heterozygote survives to adulthood. ptc1/– mice, like PTC1/–
patients, have a high incidence of developmental abnormalities and
extracutaneous tumors. These mice, like mice with inactivation of
exons 6 and 7 reported by Hahn et al (1998), have varying combinations
of medulloblastomas, rhabdomyosarcomas, polydactyly, and jaw cysts
but have not been previously reported to develop BCC. We have
examined the skin of these mice (through maturity), and find that,
like PTC1/– BCNS patients, ptc1/– mice develop BCC and that these
tumors demonstrate upregulation of ptc promoter activity. Although the
skin of untreated exon 1 and 2 ptc1/– mice at 3–17 mo of age
appeared grossly normal, 30% (26 of 85) of biopsied mice had
microscopically detectable basaloid cell proliferations (average cross-
sectional area 0.002 mm2), some resembling superficial BCC and
others resembling a related follicular germinative tumor known as
trichoblastoma. Most of these basaloid cell proliferations appeared after
9 mo of age (25 of 26) (Aszterbaum et al, in preparation). In contrast,
none of 27 WT littermate controls had a skin tumor detectable in
biopsied skin. These findings further emphasize the importance of
PTC inactivation in BCC and BCC-like tumors. Furthermore, the ptc
heterozygote KO mouse is the first and only model of murine BCC
tumorigenesis in which mice survive to adulthood and produce viable
offspring (Table I).
MUTATIONS IN OTHER GENES
Oncogenes and tumor suppressor genes commonly implicated in
extracutaneous tumorigenesis, including ras and p53, have also been
implicated in BCC tumorigenesis. p53 is an important cell cycle
inhibitor and a regulator of DNA repair and apoptosis of cells with
damaged DNA. Almost half of all types of sporadic human tumors
occurring in the general population have mutations of p53 (Beroud
et al, 1996). In normal appearing UV-exposed human epidermis, islands
of keratinocytes immunostain for mutant p53 (Jonason et al, 1996).
These islands suggest that p53 mutant cells may be clonally expanded
and may have a selective growth advantage over cells WT for p53.
p53 mutations have been identified in 50% of BCC, and 65% of these
are UV-type mutations (Brash et al, 1991; Rady et al, 1992; Campbell
et al, 1993; Moles et al, 1993; Ziegler et al, 1993; Kubo et al, 1994;
van der Riet et al, 1994; Gailani et al, 1996a). As mentioned previously,
9q (PTC locus) LOH in BCC does not correlate with p53 UV
signature mutations; however, in situ detection of high levels of PTC
mRNA in BCC was accompanied by positive p53 immunostaining in
two-thirds of tumors (Unden et al, 1997). These findings suggest a
collaborative role for p53 in BCC tumorigenesis, but no currently
available evidence confirms a direct interaction between p53 and HH
pathway genes.
BCC tumor incidence and location has also been associated with
polymorphisms in glutathione synthetase (GST) genes, which are
important in detoxification of reactive oxygen species, and in
cytochrome p450 (CYP) genes, which are important in metabolizing
environmental carcinogens such as nitrosamines and polycyclic aromatic
hydrocarbons. In patients who present with at least one BCC, those
which are GSTT1 null or have polymorphisms in GSTM1 or CYP2D6
have a significantly decreased time before the appearance of a new
BCC (Lear et al, 1997). Therefore these genes may play an important
role in BCC tumorigenesis.
The ras oncogenes, comprised of H-ras, N-ras, and K-ras, are mutant
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in a variety of human cancers, including breast, bladder, and skin
cancers. Single base substitutions have been found in H-ras or K-ras
in 13% to 31% of screened BCC (van der Schroeff et al, 1990; Pierceall
et al, 1991b). These activating mutations have been identified in BCC
from sun-exposed sites (neck, face, and shoulder), and some are UV
signature type mutations (Pierceall et al, 1991b). In patients with
nonmelanoma skin cancer, there is a high incidence (36% for patients
with BCC and 90% for patients with SCC) of Ha-ras LOH in normal
appearing skin (Ananthaswamy et al, 1989). The ras GTPase activating
protein (rasGAP) gene, both a downregulator of ras and an effector of
downstream ras signaling, has also been found to be mutant in human
BCC (Friedman et al, 1993). These findings suggest a potential
interaction between the ras signaling pathway and BCC and tumor
promotion.
In vitro studies suggest that the ras gene may be involved in HH
pathway regulation. Immortalized human keratinocytes containing p53
mutations, HaCaT cells, express markedly increased levels of PTC
message when transfected with EJ-ras, a mutated c-Ha-ras gene. SMO
is also overexpressed in HaCaT cell lines, although with less consistency,
and SMO expression level in HaCaT cell lines correlates with doubling
time – the highest level of SMO expression is associated with the
shortest doubling time. Overall, EJ-ras transfection of HaCaT cells
results in an almost 3-fold increase in PTC message and a 30% increase
in SMO expression (Kallassy et al, 1997).
CONCLUSION
The molecular mechanisms by which UV radiation transforms normal
basal keratinocytes to BCC cancer cells is not fully elucidated. This
review has provided an overview of some molecular alterations
detected in clinically apparent human BCC with particular emphasis
on mutations in the HH pathway genes. Animal and in vitro models
herein discussed establish the importance of HH pathway dysregulation
in BCC tumorigenesis. Furthermore, the high frequency of UVB
signature mutations in PTC indicates that UV radiation is important
to HH pathway gene mutagenesis. Therefore, we conclude that existing
genetic evidence supports current epidemiologic evidence that UVR
is central to the pathogenesis of human BCC. Mutations in other
tumor suppressor genes or oncogenes including p53 and ras may
potentiate tumor progression via interaction with the HH pathway;
however, future studies will attempt to replicate UV mediated tumori-
genesis in animal models and further elucidate the molecular mechan-
isms of BCC tumorigenesis.
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